Aytu Biopharma (AYTU) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 1,829.52% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 58.76% |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | 35.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 35.90% |
| Dec 31, 2025 | 26.18% |
| Sep 30, 2025 | 53.39% |
| Jun 30, 2025 | 349.42% |
| Mar 31, 2025 | -2,468.50% |
| Dec 31, 2024 | 2,247.41% |
| Sep 30, 2024 | -528.44% |
| Jun 30, 2024 | -111.92% |
| Mar 31, 2024 | 91.24% |
| Dec 31, 2023 | 94.49% |
| Sep 30, 2023 | 97.69% |
| Jun 30, 2023 | 232.08% |
| Mar 31, 2023 | 68.18% |
| Dec 31, 2022 | 72.18% |
| Sep 30, 2022 | -140.74% |
| Jun 30, 2022 | -204.99% |
| Dec 31, 2021 | -203.16% |
| Sep 30, 2021 | 52.50% |
| Jun 30, 2021 | 448.21% |
| Dec 31, 2020 | 72.57% |